Abstract
We evaluate the effect of a standardized dietary supplementation with ω-3 polyunsaturated fatty acids (n-3 PUFAs) on the level of some markers of vascular remodeling in patients with combined dyslipidemia. Three hundred and thirty-three patients received placebo or n-3 PUFAs for 6 months. We evaluated body mass index, glycemic profile, blood pressure, lipid profile, lipoprotein(a), plasminogen activator inhibitor-1, homocysteine, fibrinogen, high-sensitivity C reactive protein, ADP, MMP-2 and MMP-9, and tissue inhibitors of metalloproteinase-1 and -2. A significant increase of high-density lipoprotein-cholesterol, and a significant decrease of triglycerides were present after 3 and 6 months with n-3 PUFAs intake. A significant plasminogen activator inhibitor-1, fibrinogen and high-sensitivity C reactive protein decrease was obtained after 3 and 6 months and a significant ADP increase was observed after 3 and 6 months of n-3 PUFAs. A significant MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 and tissue inhibitors of metalloproteinase-2 decrease was obtained after 6 months compared to the baseline value with n-3 PUFAs intake. n-3 PUFAs give a better lipid profile and a better improvement of coagulation, fibrinolytic and inflammatory parameters than placebo. Furthermore, lowers levels of MMP-2, MMP-9 and their tissue inhibitors are obtained with n-3 PUFAs compared to placebo.
| Original language | English |
|---|---|
| Pages (from-to) | 1239-1247 |
| Number of pages | 9 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 10 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Jun 2009 |
Fingerprint
Keywords
- ω-3 polyunsaturated fatty acids
- Combined dyslipidemia
- Inflammatory parameters
- Matrix metalloproteinases
- Tissue inhibitors of metalloproteinases
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
Cite this
Effects of long chain ω-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. / Derosa, G.; Maffioli, P.; D'Angelo, A.; Salvadeo, S. A T; Ferrari, I.; Fogari, E.; Gravina, A.; Mereu, R.; Randazzo, S.; Cicero, A. F G.
In: Expert Opinion on Pharmacotherapy, Vol. 10, No. 8, 06.2009, p. 1239-1247.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of long chain ω-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients
AU - Derosa, G.
AU - Maffioli, P.
AU - D'Angelo, A.
AU - Salvadeo, S. A T
AU - Ferrari, I.
AU - Fogari, E.
AU - Gravina, A.
AU - Mereu, R.
AU - Randazzo, S.
AU - Cicero, A. F G
PY - 2009/6
Y1 - 2009/6
N2 - We evaluate the effect of a standardized dietary supplementation with ω-3 polyunsaturated fatty acids (n-3 PUFAs) on the level of some markers of vascular remodeling in patients with combined dyslipidemia. Three hundred and thirty-three patients received placebo or n-3 PUFAs for 6 months. We evaluated body mass index, glycemic profile, blood pressure, lipid profile, lipoprotein(a), plasminogen activator inhibitor-1, homocysteine, fibrinogen, high-sensitivity C reactive protein, ADP, MMP-2 and MMP-9, and tissue inhibitors of metalloproteinase-1 and -2. A significant increase of high-density lipoprotein-cholesterol, and a significant decrease of triglycerides were present after 3 and 6 months with n-3 PUFAs intake. A significant plasminogen activator inhibitor-1, fibrinogen and high-sensitivity C reactive protein decrease was obtained after 3 and 6 months and a significant ADP increase was observed after 3 and 6 months of n-3 PUFAs. A significant MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 and tissue inhibitors of metalloproteinase-2 decrease was obtained after 6 months compared to the baseline value with n-3 PUFAs intake. n-3 PUFAs give a better lipid profile and a better improvement of coagulation, fibrinolytic and inflammatory parameters than placebo. Furthermore, lowers levels of MMP-2, MMP-9 and their tissue inhibitors are obtained with n-3 PUFAs compared to placebo.
AB - We evaluate the effect of a standardized dietary supplementation with ω-3 polyunsaturated fatty acids (n-3 PUFAs) on the level of some markers of vascular remodeling in patients with combined dyslipidemia. Three hundred and thirty-three patients received placebo or n-3 PUFAs for 6 months. We evaluated body mass index, glycemic profile, blood pressure, lipid profile, lipoprotein(a), plasminogen activator inhibitor-1, homocysteine, fibrinogen, high-sensitivity C reactive protein, ADP, MMP-2 and MMP-9, and tissue inhibitors of metalloproteinase-1 and -2. A significant increase of high-density lipoprotein-cholesterol, and a significant decrease of triglycerides were present after 3 and 6 months with n-3 PUFAs intake. A significant plasminogen activator inhibitor-1, fibrinogen and high-sensitivity C reactive protein decrease was obtained after 3 and 6 months and a significant ADP increase was observed after 3 and 6 months of n-3 PUFAs. A significant MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 and tissue inhibitors of metalloproteinase-2 decrease was obtained after 6 months compared to the baseline value with n-3 PUFAs intake. n-3 PUFAs give a better lipid profile and a better improvement of coagulation, fibrinolytic and inflammatory parameters than placebo. Furthermore, lowers levels of MMP-2, MMP-9 and their tissue inhibitors are obtained with n-3 PUFAs compared to placebo.
KW - ω-3 polyunsaturated fatty acids
KW - Combined dyslipidemia
KW - Inflammatory parameters
KW - Matrix metalloproteinases
KW - Tissue inhibitors of metalloproteinases
UR - http://www.scopus.com/inward/record.url?scp=67649675091&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649675091&partnerID=8YFLogxK
U2 - 10.1517/14656560902865601
DO - 10.1517/14656560902865601
M3 - Article
C2 - 19397392
AN - SCOPUS:67649675091
VL - 10
SP - 1239
EP - 1247
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 8
ER -